5Boulman N, Levy Y, Leiba R,et al. Increased C-reactive protein levels in the polycystic ovary syndrome: a marker of cardiovascular disease[J]. J Clin Endoerinol Metab, 2004,89 :2160-2165.
2Lagrand WK, Visser CA, Hermens WT, et al. C-reactive protein as a cardiovascular risk factor.more than an epiphenomenon? Circulation,1999, 100(1 ): 96-102.
3Tracy RP. Inflammation in cardiovascular disease: cart, horse, or both.? Circulation, 1998, 97(20): 2000-2002.
4Rifai N, Tracy RP, Ridker PM. Clinical efficacy of an automated high-sensitivity C-reactive protein assay. Clin Chem, 1999, 45 (12):2136-2141.
5Roberts WL, Moulton L, Law TC, et al. Evaluation of nine automated high-sensitivity C-reactive protein methods: implications for clinical and epidemiological applications. Part 2. Clin Chem, 2001,47(3):418-425.
6Meier-Ewert HK, Ridker PM, Rifai N, et al. Absence of diurnal variation of C-reactive protein concentrations in healthy human subjects.Clin Chem, 2001,47(3): 426-430.
7Ridker PM, Cushman M, Stampfer MJ, et al. Inflammation, aspirin,and the risk of cardiovascular disease in apparently healthy men. N Engl J Med, 1997, 336(14): 973-979.
8Di Napoli M, Di Gianfilippa G, Sollecito A, et al. C-reactive protein and outcome after first-ever ischemic stroke. Stroke, 2000, 31 (1):238-239.
9Di Napoli M, Papa F, Bocola V. Prognostic influence of increased C-reactive protein and fibrinogen levels in ischemic stroke. Stroke,2001,32(1): 133-138.
10Di Napoli M, Papa F, Bocola V. C-reactive protein in ischemic stroke: an independent prognostic factor. Stroke, 2001, 32(4): 917-924.
